Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Braz. J. Pharm. Sci. (Online) ; 54(spe): e01005, 2018. tab
Artículo en Inglés | LILACS | ID: biblio-974432

RESUMEN

Dyslipidemia, diabetes, obesity and hypertension are common metabolic diseases. In the last decades, unhealthy lifestyle and aging have leads to an increased incidence of these diseases, increasing morbidity and mortality by cardiovascular causes. The treatment of metabolic diseases includes life-style interventions as healthy diet and physical exercise, as well as pharmacological interventions. Several drugs are available for the management of metabolic diseases including among others lipid-lowering antidiabetics and antihypertensive drugs. Variability in response to these drugs is influenced by both genetic and non-genetic factors. Polymorphisms in genes related to drug pharmacokinetics and pharmacodynamics have been shown to influence drug efficacy and safety. This review is focused on pharmacogenetic studies related to the management of metabolic diseases in samples of the Brazilian population. Associations of variants in drug metabolizing enzymes and transporters, drug target and metabolism-related genes with the efficacy and safety of lipid-lowering, antidiabetic and antihypertensive drugs are described. Most pharmacogenetic studies in Brazil have focused in pharmacological response to a small group of drugs, as statins and some antihypertensives, while there are almost no studies on antidiabetic and antiobesity drugs. Some studies reported significant associations of gene polymorphisms with drug response confirming previous data from other populations, whereas other works did not replicate, which may relay on the genetic admixture of our population. In conclusion, further studies are necessary considering larger sample sizes, new unexplored drugs and more genetic variants to obtain stronger conclusions to explore clinical applications of pharmacogenetic studies in our population.


Asunto(s)
Población/genética , Variantes Farmacogenómicas/fisiología , Enfermedades Metabólicas/patología , Enfermedades Metabólicas/prevención & control , Polimorfismo Genético , Brasil , Pruebas de Farmacogenómica/métodos
3.
Clinics ; 73(supl.1): e565s, 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-974948

RESUMEN

Pharmacogenetics, a major component of individualized or precision medicine, relies on human genetic diversity. The remarkable developments in sequencing technologies have revealed that the number of genetic variants modulating drug action is much higher than previously thought and that a true personalized prediction of drug response requires attention to rare mutations (minor allele frequency, MAF<1%) in addition to polymorphisms (MAF>1%) in pharmacogenes. This has major implications for the conceptual development and clinical implementation of pharmacogenetics. Drugs used in cancer treatment have been major targets of pharmacogenetics studies, encompassing both germline polymorphisms and somatic variants in the tumor genome. The present overview, however, has a narrower scope and is focused on germline cancer pharmacogenetics, more specifically, on drug/gene pairs for which pharmacogenetics-informed prescription guidelines have been published by the Clinical Pharmacogenetics Implementation Consortium and/or the Dutch Pharmacogenetic Working Group, namely, thiopurines/TPMT, fluoropyrimidines/UGT1A1, irinotecan/UGT1A1 and tamoxifen/CYP2D6. I begin by reviewing the general principles of pharmacogenetics-informed prescription, pharmacogenetics testing and the perceived barriers to the adoption of routine pharmacogenetics testing in clinical practice. Then, I highlight aspects of the pharmacogenetics testing of the selected drug-gene pairs and finally present pharmacogenetics data from Brazilian studies pertinent to these drug-gene pairs. I conclude with the notion that pharmacogenetics testing has the potential to greatly benefit patients by enabling precision medicine applied to drug therapy, ensuring better efficacy and reducing the risk of adverse effects.


Asunto(s)
Humanos , Pruebas de Farmacogenómica/métodos , Neoplasias/genética , Neoplasias/tratamiento farmacológico , Polimorfismo Genético , Brasil , Medicina Basada en la Evidencia , Medicina de Precisión , Mutación
4.
Annals of Laboratory Medicine ; : 180-193, 2017.
Artículo en Inglés | WPRIM | ID: wpr-8638

RESUMEN

Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.


Asunto(s)
Anticoagulantes/uso terapéutico , Antidepresivos/uso terapéutico , Antimetabolitos Antineoplásicos/uso terapéutico , Antituberculosos/uso terapéutico , Arilamina N-Acetiltransferasa/genética , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Citocromo P-450 CYP2C19/genética , Citocromo P-450 CYP2C9/genética , Citocromo P-450 CYP2D6/genética , Trastorno Depresivo/tratamiento farmacológico , Genotipo , Isoniazida/uso terapéutico , Laboratorios de Hospital/normas , Metiltransferasas/genética , Pruebas de Farmacogenómica/métodos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Embolia Pulmonar/tratamiento farmacológico , Ticlopidina/análogos & derivados , Tuberculosis/tratamiento farmacológico , Vitamina K Epóxido Reductasas/genética , Warfarina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA